Gide advises Inovo VC on its investment in Ingenix.AI

Gide’s Warsaw office, with support from the London office, advised Inovo Fund III SCSp, a fund owned by Inovo VC, one of the leading venture capital funds operating in Poland and the CEE region, on its investment in Ingenix.AI Ltd, a biotech company developing a generative AI model that simulates clinical trials.

The team from Gide’s Warsaw office, which included Paweł Grześkowiak (advocate, partner), Wojciech Czyżewski (advocate, counsel), Magdalena Zawiślak (trainee attorney-at-law, associate) and Mateusz Więckowski (advocate, associate), supported the client at every stage of the investment process, including during the due diligence investigation, preparing the investment agreement and shareholders’ agreement, and the finalisation of the transaction.

Inovo VC is an investment fund that supports early-stage startups from Poland and the CEE region, helping them build global brands.

Ingenix.AI is a UK-based biotechnology company developing a foundational model for clinical trials. The model is trained on genomic, transcriptomic, proteomic, imaging and phenotypic data.